# Amneal Pharmaceuticals

> Amneal develops, manufactures and distributes generic, specialty and biosimilar medicines. Founded by brothers Chirag and Chintu Patel in 2002, the Bridgewater-based public company combines complex pharmaceutical development with manufacturing and distribution, including AvKARE’s federal healthcare business. It reported $3.02 billion in 2025 net revenue.

- **Founded:** 2002
- **Headquarters:** Bridgewater, United States
- **Founders:** Chirag Patel (Co-Founder and Co-Chief Executive Officer), Chintu Patel (Co-Founder and Co-Chief Executive Officer)
- **Products:** Complex generic medicines, CREXONT, RYTARY, UNITHROID, BREKIYA
- **Notable:** Built a portfolio of approximately 300 medicines., FDA approval of CREXONT in August 2024., Completed Kashiv BioSciences acquisition in August 2026.

## Products & services

- **Complex generic medicines** — Oral solids and liquids, injectables, ophthalmics, topicals, softgels, inhalation products and transdermals.
- **CREXONT** — Extended-release carbidopa/levodopa capsules for Parkinson’s disease; FDA-approved in August 2024.
- **RYTARY** — Extended-release carbidopa/levodopa capsules within the specialty neurology portfolio.
- **UNITHROID** — Levothyroxine sodium tablets in the endocrinology portfolio.
- **BREKIYA** — Dihydroergotamine mesylate autoinjector for acute migraine and cluster headache treatment in adults.
- **Biosimilars** — Portfolio includes oncology-supportive care medicines and FDA-approved denosumab biosimilars Boncresa and Oziltus; approval and commercial availability are distinct.
- **AvKARE** — Pharmaceutical and medical-product distribution for federal, retail and institutional customers.
- **Lanreotide injection** — 120 mg/0.5 mL single-dose prefilled syringe, approved and launched in September 2026.

## Achievements

- Built a portfolio of approximately 300 medicines.
- FDA approval of CREXONT in August 2024.
- Completed Kashiv BioSciences acquisition in August 2026.
- Reported $72 million GAAP net income attributable to Amneal in 2025.

## Latest updates

- **2026-10** — Announced that third-quarter results will be reported November 3, 2026; these results were not yet available at the research date.
- **2026-09** — FDA approval and immediate launch of lanreotide injection announced September 18.
- **2026-08** — Completed acquisition of Kashiv BioSciences on August 10.
- **2026-07** — Reported second-quarter net revenue of $796 million and raised full-year net revenue guidance to $3.10-$3.20 billion; guidance is a forecast.
- **2026-03** — Voluntarily recalled one magnesium sulfate IV-bag lot following a product mix-up; reported no associated adverse events at announcement.

## Links

- Website: https://amneal.com
- LinkedIn: https://www.linkedin.com/company/amneal-pharmaceuticals/
- Twitter/X: https://twitter.com/AmnealPharma
- YouTube: https://www.youtube.com/channel/UCQ1VlP0GTdfiL_WrJzIlzOQ
- Facebook: https://www.facebook.com/people/Amneal-Pharmaceuticals/100076381024161/

---

Profile page: https://yespress.io/amneal-pharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-10-22